The chemokine CCL27 has chemoattractant properties for memory T cells and has been implicated in skin allergic reactions. The present study reports the expression in the brain of two CCL27 splice variants localized in the cerebral cortex and limbic regions. CCL27-like immunoreactivity was identified mainly in neurons. Variant 1 was found elevated in the olfactory bulbs during allergic inflammation induced by intranasal challenge with allergen. This was accompanied by the presence of T cells in the olfactory bulbs. Intranasal administration of neutralizing antibodies against CCL27 reduced the presence of T cells in the olfactory bulbs suggesting a function in T cell activity in the brain.
Introduction
The chemokine CCL27 is a member of the beta family of chemokines and has been shown to display specific homing properties for memory CD4+ T cells expressing the cutaneous lymphocyte antigen (CLA) (Morales et al., 1999) . Initial studies found that CCL27 was constitutively and selectively expressed by keratinocytes in the skin and because of its homing properties for memory T cells it was named cutaneous T cell attracting chemokine (CTACK) (Morales et al., 1999) . This chemokine has important functions in skin lymphocyte trafficking and inflammation (Morales et al., 1999; Homey et al., 2002) and plays a pivotal role on skin allergic processes including atopic dermatitis and delayed type hypersensitivity reactions in both human and experimental animal models (Homey et al., 2002; Huang et al., 2008; Kunkel and Butcher, 2002; Vestergaard et al., 2004a,b; Reiss et al., 2001) . Increased production of CCL27 and expression of its cognate receptor CCR10 has been reported in the skin of atopic dermatitis patients (Homey et al., 2002) . Further, the role of CCL27 in skin allergy is supported by studies showing that overexpression of CCL27 in transgenic mice promotes the development of skin contact hypersensitivity and the production of interleukin-4 (Kagami et al., 2008) and CCL27 was shown essential for the development of atopic skin inflammatory processes in an IL-4 transgenic mice model of atopic dermatitis (Chen et al., 2006) . Lastly, CCL27 may present a viable target for the treatment of skin cancer (Gao et al., 2009 (Gao et al., , 2003 Pivarcsi et al., 2007) . CCR10 is the only receptor known to bind CCL27 and mediate its effects (Homey et al., 2000; Jarmin et al., 2000) . The mRNA and genomic sequence for CCL27 were contemporarily obtained by several groups resulting in different names including ESkine (stem cell derived chemokine) (Baird et al., 1999) , ILC (interleukin-11 receptor alphalocus chemokine) (Ishikawa-Mochizuki et al., 1999) and ALP (amino terminal peptide sequence) (Hromas et al., 1999) . The genomic sequence is located in chromosome 4 in mice and chromosome 9 in human and partially overlaps, in the opposite direction, with that of interleukin-11 receptor alpha (Baird et al., 1999; Ishikawa-Mochizuki et al., 1999) . Interestingly, CCL27, which is encoded in 3 exons, has 2 different isoforms resulting from alternative splicing of exon 1 which gives the canonical secreted mature form of CCL27 expressed in the skin and placenta and a second protein with a different exon 1 called PESKY, which is highly expressed in the brain and testis (Morales et al., 1999; Baird et al., 1999; Gortz et al., 2002; Nibbs and Graham, 2003) . The current nomenclature for these transcripts assigned the name CCL27 
